NIHB Pharmacist
Focusing on Naloxone, with a bit of Hep C and HIV Coverage
Naloxone (Narcan)
Naloxone allows for the reversal of respiratory depression:
Very safe!
Treatment of Chronic Hepatitis C
Effective March 31st 2017, the Non-Insured Health Benefits (NIHB) Program expanded coverage criteria and added new medications for the treatment of hepatitis C as limited use (LU) benefits:
Harvoni (ledipasvir/sofosbuvir)
Sovaldi (sofosbuvir)
Epclusa (sofosbuvir/velpatasvir)
Zepatier (elbasvir/grazoprevir)
Daklinza (daclatasvir)
Sunvepra (asunaprevir)
Ibavyr (ribavirin)
Hep C Coverage Criteria
Treatment is prescribed by a hepatologist, gastroenterologist, or infectious disease specialist (or other prescriber experienced in treating patients with chronic hepatitis C); AND
Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, 6 or mixed genotype; &
Laboratory confirmed quantitative HCV RNA level taken in the last 12 months; &
Fibrosis stage of F2 or greater (Metavir scale or equivalent); OR
Fibrosis stage less than F2 AND at least one of the following:
Co-infection with human immunodeficiency virus (HIV) or hepatitis B virus
Co-existent liver disease with diagnostic evidence of fatty liver disease (Example: nonalcoholic steatohepatitis [NASH])
Post organ transplant (may include liver and/or non-liver organ transplant)
Extra-hepatic manifestations
Chronic kidney disease stage 3, 4 or 5 as defined by National Kidney Foundation Kidney Disease outcomes Quality Initiative (K/DOQI)
Diabetic patients receiving treatment with anti-diabetic drugs
Women of childbearing age who plan to get pregnant within the next 12 months
